Ineffectiveness of a four week treatment with the thromboxane synthetase inhibitor, imidazole salycilate, in reducing airway hyperresponsiveness to methacholine in asthmatics

Monaldi Archives for Chest Disease

Volumn 52, Issue 2, 1997, Pages 130-137

  Peccini, F ^a  

^a Hospital of Ubbio   (Italy)

Author keywords

Airway responsiveness; Asthma; Imidazole salycilate; Thromboxane A2

Indexed keywords

IMIDAZOLE SALICYLATE; METHACHOLINE; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANE SYNTHASE; THROMBOXANE SYNTHASE INHIBITOR;

ADULT; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PATHOGENESIS; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

EID: 0030854551     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Piper PJ, Vane JR. - Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature 1969; 233: 29-35.
2. Hamberg M, Svensson J, Samuelsson B. - Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sec USA 1975; 79: 2994-2998.